{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:10:27Z","timestamp":1788952227709,"version":"build-2803163510"},"reference-count":34,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Background: The COMPASS trial showed the benefits of dual pathway inhibition (DPI) in patients with atherosclerotic vascular disease. However, the characteristics of patients initiated on DPI have not been previously defined in clinical practice. This study aims to determine the clinical profile, management and outcomes of patients with coronary artery disease (CAD), peripheral artery disease (PAD) or both, initiating DPI using rivaroxaban 2.5 mg twice daily plus aspirin in clinical practice in Latin America.\n\nMethods: XATOA was an international, multicentre, prospective and single-arm registry that consecutively included adults with CAD, PAD or both, receiving DPI within 4 weeks before enrolment, according to clinical practice. Data from XATOA in Latin America are presented.\n\nResults: A total of 311 patients were included (mean age 67.74\u00b111.63 years, 29.6% women, 74.3% with CAD, 40.5% with PAD and 14.8% with both conditions). The most frequently reported reason for initiating DPI was the presence of existing, worsening or newly diagnosed atherothrombotic risk characteristics (74.9%). Mean follow-up was 445.2\u00b1145.7 days. The incidence of major adverse cardiovascular events, cardiovascular death, major adverse limb events, and acute or severe limb ischaemia was 1.72 (95% CI 0.63\u20133.75), 1.15 (95% CI 0.31\u20132.94), 1.15 (95% CI 0.31\u20132.95) and 0.57 (95% CI 0.07\u20132.07) per 100 patient-years, respectively. Permanent discontinuation of rivaroxaban treatment was observed in 15.8% of patients, and serious adverse events related to rivaroxaban occurred in 0.3% of patients.\n\nConclusion: Although patients with DPI in Latin America presented with a high vascular risk profile, the incidence of major adverse cardiovascular events and major adverse limb events, as well as the risk of major bleeding, remained low during follow-up. These results support the use of rivaroxaban 2.5 mg twice daily combined with aspirin in this population in clinical practice.\n\nTrial registration number: XATOA registry (NCT03746275)\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-clinical-profile-management-and-outcomes-of-patients-taking-dual-pathway-inhibition-for-cardiovascular-protection-in-clinical-practice-in-latin-america-data-from-the-xatoa-re<\/jats:p>","DOI":"10.7573\/dic.2026-1-4","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:06:12Z","timestamp":1780067172000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Clinical profile, management and outcomes of patients taking dual pathway inhibition for cardiovascular protection in clinical practice in Latin America. Data from the XATOA registry"],"prefix":"10.7573","volume":"15","author":[{"given":"Juan Rene","family":"Cornejo-Avenda\u00f1o","sequence":"first","affiliation":[{"name":"Doctors Hospital Auna, Monterrey, Nuevo Le\u00f3n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Novoa","sequence":"additional","affiliation":[{"name":"Angeles Acoxpa Hospital, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Pe\u00f3n","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de M\u00e9rida, M\u00e9rida, Yucat\u00e1n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rapallo","sequence":"additional","affiliation":[{"name":"Sanatorio Anchorena Itoiz, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ricalde Alcocer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03e36d037","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro M\u00e9dico ABC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor Alejandro","family":"Vita","sequence":"additional","affiliation":[{"name":"Sanatorio de la Mujer, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9522-5576","authenticated-orcid":false,"given":"Luis Ram\u00f3n","family":"Virgen-Carrillo","sequence":"additional","affiliation":[{"name":"Hospital Angeles Guadalajara, Guadalajara, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Felipe","family":"Barrera-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Saltillo, Saltillo, Coahuila, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ramacciotti","sequence":"additional","affiliation":[{"name":"Science Valley Research Institute, Santo Andr\u00e9, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tTsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics \u2014 2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93\u2013e621. https:\/\/doi.org\/10.1161\/CIR.0000000000001123","DOI":"10.1161\/CIR.0000000000001137"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tDagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395(10226):785\u2013794. https:\/\/doi.org\/10.1016\/S0140-6736(19)32007-0","DOI":"10.1016\/S0140-6736(19)32007-0"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tVrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u20133537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tMazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u20133700. https:\/\/doi.org\/10.1093\/eurheartj\/ehae179","DOI":"10.1093\/eurheartj\/ehae179"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tBelch JJF, Brodmann M, Baumgartner I, et al. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society\/European Society of Vascular Medicine joint statement. Atherosclerosis. 2021;338:55\u201363. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.022","DOI":"10.1016\/j.atherosclerosis.2021.09.022"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tLanas F, Soto A. Trends in mortality from ischemic heart disease in the region of the Americas, 2000\u20132019. Glob Heart. 2022;17(1):53. https:\/\/doi.org\/10.5334\/gh.1144","DOI":"10.5334\/gh.1144"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tPagan E, Chatenoud L, Rodriguez T, et al. Comparison of trends in mortality from coronary heart and cerebrovascular diseases in North and South America: 1980 to 2013. Am J Cardiol. 2017;119(6):862\u2013871. https:\/\/doi. org\/10.1016\/j.amjcard.2016.11.040","DOI":"10.1016\/j.amjcard.2016.11.040"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tPeix A, Paez D. Ischemic heart disease in Latin American women current perspective and call to action. J Nucl Cardiol. 2019;26(4):1361\u20131364. https:\/\/doi.org\/10.1007\/s12350-018-1459-5","DOI":"10.1007\/s12350-018-1459-5"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tCant\u00fa-Brito C, Chiquete E, Antezana-Castro JF, et al.; INDAGA Cardiologists Investigators. Peripheral artery disease in outpatients with a recent history of acute coronary syndrome or at high atherothrombotic risk. Vascular. 2021;29(1):92\u201399. https:\/\/doi.org\/10.1177\/1708538120938921","DOI":"10.1177\/1708538120938921"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tRocha BML, da Cunha GJL, Aguiar CMT. A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation. Cardiovasc Diagn Ther. 2021;11(1):130\u2013141. https:\/\/doi.org\/10.21037\/cdt-20-859","DOI":"10.21037\/cdt-20-859"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tHern\u00e1ndez JL, Lozano FS, Riambau V, et al. Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. Drugs Context. 2020;9:2020-5-5. https:\/\/doi.org\/10.7573\/dic.2020-5-5","DOI":"10.7573\/dic.2020-5-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tWeitz JI, Angiolillo DJ, Geisler T, Heitmeier S. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence. Thromb Haemost. 2020;120(8):1147\u20131158. https:\/\/doi. org\/10.1055\/s-0040-1713376","DOI":"10.1055\/s-0040-1713376"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tDi Fusco SA, Rizzello V, Scicchitano P, et al. ANMCO position paper: evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease. G Ital Cardiol. 2022;23(12):967\u2013976. https:\/\/doi.org\/10.1714\/3913.38965","DOI":"10.1714\/3913.38965"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tYnsaurriaga FA, Barrios V, Amaro MB, et al. Chronic coronary syndrome: overcoming clinical practice guidelines. The role of the COMPASS strategy. Curr Cardiol Rev. 2021;17(3):294\u2013305. https:\/\/doi.org\/10.2174\/15734 03X16999200817111150","DOI":"10.2174\/1573403X16999200817111150"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tEikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u20131330. https:\/\/doi.org\/10.1056\/NEJMoa1709118","DOI":"10.1056\/NEJMoa1709118"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tZhu H, Xu X, Fang X, et al. Efficacy and safety of long-term antithrombotic strategies in patients with chronic coronary syndrome: a network meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021;10(6):e019184. https:\/\/doi.org\/10.1161\/JAHA.120.019184","DOI":"10.1161\/JAHA.120.019184"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tFox KAA, Aboyans V, Debus ES, et al. Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA registry. Eur Heart J Cardiovasc Pharmacother. 2022;8(8):825\u2013836. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac028","DOI":"10.1093\/ehjcvp\/pvac028"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tFox KAA, Anand SS, Aboyans V, et al. Xarelto plus acetylsalicylic acid: treatment patterns and outcomes in patients with atherosclerosis (XATOA): rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. Am Heart J. 2020;222:166\u2013173. https:\/\/doi.org\/10.1016\/j.ahj.2020.01.015","DOI":"10.1016\/j.ahj.2020.01.015"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tVirani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013e119. https:\/\/doi.org\/10.1161\/ CIR.0000000000001168","DOI":"10.1161\/CIR.0000000000001183"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tGornik HL, Aronow HD, Goodney PP, et al. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology\/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313\u2013e1410. https:\/\/doi.org\/10.1161\/CIR.0000000000001251","DOI":"10.1161\/CIR.0000000000001251"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tDarmon A, Elbez Y, Bhatt DL, et al. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH registry. Ann Cardiol Angeiol. 2020;69(4):158\u2013166. https:\/\/doi.org\/10.1016\/j. ancard.2020.07.002","DOI":"10.1016\/j.ancard.2020.07.002"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tSheth MS, Yu B, Chu A, et al. Eligibility and implementation of rivaroxaban for secondary prevention of atherothrombosis in clinical practice \u2014 insights from the CANHEART study. J Am Heart Assoc. 2022;11(24):e026553. https:\/\/doi.org\/10.1161\/JAHA.122.026553","DOI":"10.1161\/JAHA.122.026553"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tKataruka A, Mahtta D, Akeroyd JM, et al. Eligibility for low-dose rivaroxaban based on the COMPASS trial: insights from the Veterans Affairs healthcare system. Cardiovasc Drugs Ther. 2021;35(3):533\u2013538. https:\/\/doi.org\/10.1007\/ s10557-020-07061-2","DOI":"10.1007\/s10557-020-07061-2"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tDe Luca L, Formigli D, Meessen J, et al. COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. Eur Heart J Qual Care Clin Outcomes. 2021;7(5):513\u2013520. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa054","DOI":"10.1093\/ehjqcco\/qcaa054"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tBarrios V, Escobar C, Suarez C, Garcia-Moll X, Lozano F. Clinical profile and management of patient patients with ischemic heart disease and\/or peripheral artery disease in clinical practice: the APALUSA study. J Clin Med. 2022;11(12):3554. https:\/\/doi.org\/10.3390\/jcm11123554","DOI":"10.3390\/jcm11123554"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tRuiz-Beltran AM, Alcaraz-Guzman A, Campos-Franco DR, et al. Risk factors control after an acute coronary syndrome and association with major adverse cardiovascular events: a single center experience in Latin- America. High Blood Press Cardiovasc Prev. 2023;30(2):161\u2013169. https:\/\/doi.org\/10.1007\/s40292-023-00560-x","DOI":"10.1007\/s40292-023-00560-x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tVanassche T, Verhamme P, Anand SS, et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: an analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2020;27(3):296\u2013307. https:\/\/doi.org\/10.1177\/2047487319882154","DOI":"10.1177\/2047487319882154"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tCesaro A, Gragnano F, Calabr\u00f2 P, et al. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the START-ANTIPLATELET registry. Int J Cardiol. 2021;345:7\u201313. https:\/\/doi.org\/10.1016\/j.ijcard.2021.10.138","DOI":"10.1093\/eurheartj\/suab140.013"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tDagenais GR, Dyal L, Bosch JJ, et al. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 2021;107(14):1130\u20131137. https:\/\/doi.org\/10.1136\/ heartjnl-2020-318758","DOI":"10.1136\/heartjnl-2020-318758"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tEikelboom JW, Bosch J, Connolly SJ, et al. Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(8):786\u2013795. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac023","DOI":"10.1093\/ehjcvp\/pvac023"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tBranch KRH, Probstfield JL, Bosch J, et al. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: the COMPASS trial. Am Heart J. 2023;258:60\u201368. https:\/\/ doi.org\/10.1016\/j.ahj.2023.01.008","DOI":"10.1016\/j.ahj.2023.01.008"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tLamy A, Eikelboom J, Tong W, et al. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes. 2023;9(3):286\u2013294. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac054","DOI":"10.1093\/ehjqcco\/qcac054"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tFeng T, Zheng Z, Gao S, et al. Cost-effectiveness analysis of rivaroxaban in Chinese patients with stable cardiovascular disease. Front Pharmacol. 2022;13:921387. https:\/\/doi.org\/10.3389\/fphar.2022.921387","DOI":"10.3389\/fphar.2022.921387"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tTsaban G, Alnsasra H, El Nasasra A, et al. Aspirin with low-dose ticagrelor or with low-dose rivaroxaban for secondary prevention: a cost per outcome analysis. Am J Cardiovasc Drugs. 2022;22(6):677\u2013683. https:\/\/ doi.org\/10.1007\/s40256-022-00543-8","DOI":"10.1007\/s40256-022-00543-8"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/05\/dic.2026-1-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:45Z","timestamp":1788949005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/clinical-profile-management-and-outcomes-of-patients-taking-dual-pathway-inhibition-for-cardiovascular-protection-in-clinical-practice-in-latin-america-data-from-the-xatoa-registry"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-1-4","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"dic.2026-1-4"}}